Veracyte received regulatory authorization from the New York State Department of Health for its genomic test for idiopathic pulmonary fibrosis (IPF).

The Envisia Genomic Classifier is the first commercially available test that doesn’t require surgery to distinguish IPF from other interstitial lung diseases.

The genomic test uses RNA sequencing and machine learning to recognize the pattern of usual interstitial pneumonia, an indicator of IPF.